Liafensine
- Generic Name
- Liafensine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H22N4
- CAS Number
- 1198790-53-2
- Unique Ingredient Identifier
- R34ID086Z6
- Background
Liafensine is under investigation in clinical trial NCT00892840 (Multiple-Ascending Dose Study).
- Associated Conditions
- -
- Associated Therapies
- -
A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 197
- Registration Number
- NCT05113771
- Locations
- πΊπΈ
University of Alabama at Birmingham, Huntsville, Alabama, United States
πΊπΈCollaborative Neuroschience Research, LLC, Garden Grove, California, United States
πΊπΈBehavioral Research Specialists, LLC, Glendale, California, United States
Japanese Phase 1 Multiple Ascending Dose (MAD) Study
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2013-06-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 57
- Registration Number
- NCT01396252
- Locations
- π―π΅
Local Institution, Taito-Ku, Tokyo, Japan
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
- Conditions
- Interventions
- First Posted Date
- 2011-06-08
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 976
- Registration Number
- NCT01369095
- Locations
- πΊπΈ
Mclean Hospital, Belmont, Massachusetts, United States
πΊπΈVirginia Commonwealth University, Richmond, Virginia, United States
πΊπΈPacific Clinical Research Medical Group, Orange, California, United States
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
- Conditions
- Interventions
- First Posted Date
- 2011-05-27
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 789
- Registration Number
- NCT01361555
- Locations
- πΊπΈ
Red Oak Psychiatry Associates, Pa, Houston, Texas, United States
πΊπΈCalifornia Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States
πΊπΈSchuster Medical Research Institute, Sherman Oaks, California, United States
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
- Conditions
- Interventions
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 889
- Registration Number
- NCT01309945
- Locations
- πΊπΈ
Univ Of Penn, Philadelphia, Pennsylvania, United States
πΊπΈPsychiatric Consultants, Pc, Franklin, Tennessee, United States
πΊπΈPacific Clinical Research Medical Group, Upland, California, United States
Single Dose Study of BMS-820836
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 68
- Registration Number
- NCT00964912
- Locations
- π¨π¦
Local Institution, Toronto, Ontario, Canada
Multiple-Ascending Dose Study
- First Posted Date
- 2009-05-05
- Last Posted Date
- 2011-02-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 57
- Registration Number
- NCT00892840
- Locations
- πΈπͺ
Local Institution, Uppsala, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.